Renal Diseases / Nephrology
Showing all 2 results
-
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $5.2 billion by 2030. -
Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach $13 billion by 2030.